Melatonin Should NOT Be Used as First-Line Treatment for Primary Insomnia in Adults
The American Academy of Sleep Medicine (AASM) explicitly recommends AGAINST using melatonin for treatment of sleep onset or sleep maintenance insomnia in adults. 1 This is a weak recommendation based on low to very low quality evidence showing minimal clinical benefit.
Key Guideline Recommendation
The 2017 AASM Clinical Practice Guideline clearly states: "We suggest that clinicians not use melatonin as a treatment for sleep onset or sleep maintenance insomnia (versus no treatment) in adults." This recommendation was based on trials using 2 mg doses of melatonin. 1
Why Melatonin Fails for Primary Insomnia
The evidence demonstrates melatonin's ineffectiveness:
- Sleep latency reduction: Only 8.9 minutes (clinically insignificant) 1
- Total sleep time increase: Only 2.2 minutes versus placebo 1
- Wake after sleep onset: Actually increased by 8.5 minutes 1
- Quality of sleep: Minimal improvement (+0.21 SMD) below clinical significance threshold 1
The AASM task force concluded that benefits approximately equal harms, with very low quality evidence due to heterogeneity, imprecision, and publication bias. 1
Important Exception: Elderly Patients (≥55 Years)
There is a notable exception for older adults. The prolonged-release melatonin 2 mg formulation showed some benefit specifically in patients aged 55-80 years:
- Elderly patients (65-80 years) showed sleep latency reduction of 19.1 minutes at 3 weeks and 25.9 minutes at 19 weeks 1
- This benefit held when age range expanded to 55-80 years, but not below age 55 1
- The 2 mg prolonged-release formulation is approved in the EU for patients ≥55 years 2
If Melatonin Is Used Despite Guidelines
When clinicians choose to use melatonin despite the negative recommendation, recent evidence suggests optimization strategies:
Dosing: 4 mg/day appears optimal (not the commonly used 2 mg) 3
Timing: Administer 3 hours before desired bedtime (not 30 minutes as commonly practiced) 3, 4. Some sources suggest 1-2 hours before bedtime for prolonged-release formulations 2, 5
Duration: Can be used for 3-13 weeks without tolerance, withdrawal, or rebound insomnia 2, 6, 5
Preferred Alternatives from Guidelines
The AASM recommends these agents OVER melatonin for insomnia 1:
- Sleep onset insomnia: Zaleplon 10 mg, triazolam 0.25 mg, ramelteon 8 mg
- Sleep maintenance insomnia: Suvorexant 10-20 mg, doxepin 3-6 mg
- Both onset and maintenance: Eszopiclone 2-3 mg, zolpidem 10 mg, temazepam 15 mg
Critical Pitfalls to Avoid
Misdiagnosing circadian rhythm disorders as primary insomnia - Melatonin has clearer efficacy in circadian disorders (delayed sleep phase, jet lag) than primary insomnia 7
Using supraphysiological doses reflexively - Melatonin acts primarily as a chronobiotic; timing matters more than dose 7
Assuming "natural" means effective - Despite widespread perception as benign, evidence does not support efficacy for primary insomnia 1
Ignoring formulation variability - Over-the-counter preparations have substantial inconsistency 7
Contraindications and Safety
Melatonin appears well-tolerated with minimal serious adverse effects 8, 2, 6, 5. However:
- Safety data for prolonged use (>12 months) in older adults is limited 9
- No suppression of endogenous melatonin production even after 12 months 6
- Mild side effects at usual doses 10
- Favorable safety profile compared to benzodiazepines (which are associated with dementia risk) 8
The bottom line: Melatonin should not be first-line therapy for primary insomnia in adults based on current guidelines. Consider FDA-approved hypnotics or melatonin receptor agonists instead. Reserve melatonin for circadian rhythm disorders or elderly patients (≥55 years) with insomnia, using prolonged-release 2 mg formulations.